Carl Sterritt Named Chief Executive Officer for Lunac Therapeutics

Lunac Therapeutics has selected Carl Sterritt to lead the company as its next Chief Executive Officer. Carl brings a strong foundation in the pharmaceutical industry, particularly as it relates to pharmaceutical research, development and commercialization. He was most recently the Founder and Chief Executive Officer of Shield Therapeutics. His leadership experience includes executive roles with Encysive, Lung Rx, and United Therapeutics. He began his career as a Project Manager with Quintiles. 

Lunac Therapeutics is a drug discovery spin-out from University of Leeds, developing next generation oral anticoagulant therapies.